Evidence map›Paper›PMID 30219203›Full record

ArticleImmunobiology2018

Effective B cell activation in vitro during viremic HIV-1 infection with surrogate T cell stimulation.

Lindsay K Nicholson, Harsh Pratap, Elisabeth Bowers, Elise Gunzburger, Srinivasa R Bandi, Edward M Gardner, Brent E Palmer, Timothy Wright, John Kittelson, Edward N Janoff

Abstract read
In one paragraph

Article in Immunobiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Lindsay K NicholsonMucosal and Vaccine Research Program Colorado (MAVRC), United States; Departments of Medicine, University of Colorado Denver, Aurora, CO, United States; Denver Veterans Affairs Medical Center, Denver, CO, United States.
Harsh PratapMucosal and Vaccine Research Program Colorado (MAVRC), United States; Departments of Medicine, University of Colorado Denver, Aurora, CO, United States; Denver Veterans Affairs Medical Center, Denver, CO, United States.
Elisabeth BowersMucosal and Vaccine Research Program Colorado (MAVRC), United States; Departments of Medicine, University of Colorado Denver, Aurora, CO, United States; Denver Veterans Affairs Medical Center, Denver, CO, United States.
Elise GunzburgerDepartments of Biostatistics, University of Colorado Denver, Aurora, CO, United States.
Srinivasa R BandiMucosal and Vaccine Research Program Colorado (MAVRC), United States; Departments of Medicine, University of Colorado Denver, Aurora, CO, United States.
Edward M GardnerDepartments of Medicine, University of Colorado Denver, Aurora, CO, United States; Denver Health and Hospital Authority, Denver, CO, United States.
Brent E PalmerMucosal and Vaccine Research Program Colorado (MAVRC), United States; Departments of Medicine, University of Colorado Denver, Aurora, CO, United States.
Timothy WrightDenver Health and Hospital Authority, Denver, CO, United States.
John KittelsonMucosal and Vaccine Research Program Colorado (MAVRC), United States; Departments of Biostatistics, University of Colorado Denver, Aurora, CO, United States.
Edward N JanoffMucosal and Vaccine Research Program Colorado (MAVRC), United States; Departments of Medicine, University of Colorado Denver, Aurora, CO, United States; Denver Veterans Affairs Medical Center, Denver, CO, United States. Electronic address: Edward.Janoff@ucdenver.edu.
Denver VA Medical Center · USUniversity of Colorado Denver · USDenver Health Medical Center · USUniversity of Colorado Hospital · US

Funding

Mechanisms of Impaired HIV-associated B cell and Pneumococcal Vaccine responsesR01AI108479 · NIAID · UNIVERSITY OF COLORADO DENVER · PI JANOFF, EDWARD N · 2014 to 2018
$2.3M
Impact of HIV-1 and Aging on Mucosal Vaccine ResponsesI01CX001464 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI JANOFF, EDWARD N · 2017 to 2021
–
CSRD VA I01 CX001464NIAID NIH HHS R01 AI108479
6 · The paper itself

Abstract

Identifying HIV-1-associated B cell defects and responses to activation may direct interventions to circumvent their impaired antibody responses to infection and vaccines. Among 34 viremic HIV-1-infected and 20 seronegative control adults, we measured baseline frequencies and activation of B and T cell subsets, expression of activation-induced cytidine deaminase (AID), potential determinants of B cell activation in vivo and B and T cell responses in vitro. At baseline, HIV-1 infection was associated with increased IgM memory and decreased anergic cell frequencies, as well as increased activation in all 10 B cell subsets compared with controls. HIV-1 status, T

Indexed as

ViremiaAdultBiomarkersB-LymphocytesCell CommunicationFemaleHIV-1HIV InfectionsHumansImmunophenotypingLymphocyte ActivationMaleMiddle AgedT-LymphocytesBiomarkersB cellsCellular activationCellular immunologyHIVT cells

Identifiers

PMID30219203
PMCPMC6264910
OpenAlexW2890906526

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.